IMW 2021 | Optimal treatment strategies for multiple myeloma
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, outlines the treatment options currently available for multiple myeloma in both transplant-eligible and ineligible patients. Prof. Moreau explains that the optimal treatment for patients ineligible for autologous stem cell transplantation (ASCT) is most likely the combination of daratumumab, lenalidomide and dexamethasone (DRd), offering both progression-free survival (PFS) and overall survival benefits, highlighting data from the MAIA trial (NCT02252172). Prof. Moreau also highlights the use of bortezomib, melphalan and prednisone (D-VMP), as investigated in the ALCYONE trial (NCT02195479), and daratumumab plus bortezomib, lenalidomide and dexamethasone (VRd). For transplant-eligible patients, Prof. Moreau proposes either VRd or bortezomib, thalidomide and dexamethasone (VTD) plus daratumumab for induction therapy, followed by transplantation and then lenalidomide for maintenance therapy. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
